开盘能dt吗？_老虎社区_美港股上老虎

meme股探测器
2023-05-03

开盘能dt吗？

Aptorum's subsidiary Paths Innovation to merge with Universal Sequencing Technology, shares up 8.3%

Aptorum Group (NASDAQ:APM) is up 8.3% after announcing a non-binding Letter of Intent to merge its s

Aptorum's subsidiary Paths Innovation to merge with Universal Sequencing Technology, shares up 8.3%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":658717741,"tweetId":"658717741","gmtCreate":1683118884183,"gmtModify":1683118885809,"author":{"id":3573894597894015,"authorId":3573894597894015,"authorIdStr":"3573894597894015","name":"meme股探测器","avatar":"https://static.tigerbbs.com/0afcfdaf70dd438f493eb33b59464e55","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>开盘能dt吗？</p></body></html>","htmlText":"<html><head></head><body><p>开盘能dt吗？</p></body></html>","text":"开盘能dt吗？","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/658717741","repostId":2332672800,"repostType":2,"repost":{"id":"2332672800","pubTimestamp":1682954200,"share":"https://www.laohu8.com/m/news/2332672800?lang=&edition=full","pubTime":"2023-05-01 23:16","market":"us","language":"en","title":"Aptorum's subsidiary Paths Innovation to merge with Universal Sequencing Technology, shares up 8.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2332672800","media":"seekingalpha","summary":"Aptorum Group (NASDAQ:APM) is up 8.3% after announcing a non-binding Letter of Intent to merge its s","content":"<html><body><ul> <li>Aptorum Group (<span>NASDAQ:APM</span>) is <font color=\"green\">up 8.3%</font> after announcing a non-binding Letter of Intent to merge its subsidiary Paths Innovation Limited with Universal Sequencing Technology.</li> <li>Paths Innovation Limited, which is majority-owned by Aptorum, holds the PathsDx technology through its subsidiary Paths Diagnostics. This liquid biopsy Next-Generation Sequencing (NGS) technology is used for diagnosing infectious diseases.</li> <li>As part of the transaction, upon closing, Aptorum's subsidiary Aptorum Therapeutics will become a shareholder in the combined company.</li> <li>Press Release</li> </ul></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptorum's subsidiary Paths Innovation to merge with Universal Sequencing Technology, shares up 8.3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptorum's subsidiary Paths Innovation to merge with Universal Sequencing Technology, shares up 8.3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-01 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3962666-aptorums-subsidiary-paths-innovation-to-merge-with-universal-sequencing-technology-shares-up-83><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aptorum Group (NASDAQ:APM) is up 8.3% after announcing a non-binding Letter of Intent to merge its subsidiary Paths Innovation Limited with Universal Sequencing Technology. Paths Innovation Limited, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3962666-aptorums-subsidiary-paths-innovation-to-merge-with-universal-sequencing-technology-shares-up-83\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1402430797/image_1402430797.jpg","relate_stocks":{"BK4179":"石油天然气设备与服务","BGNE":"百济神州","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","UVV":"环球烟草","BK4588":"碎股","BK4505":"高瓴资本持仓","BK4139":"生物科技","NGS":"Natural Gas Services Group Inc","BK4585":"ETF&股票定投概念","BK4504":"桥水持仓","BK4075":"烟草","BK4526":"热门中概股","APM":"知临集团"},"source_url":"https://seekingalpha.com/news/3962666-aptorums-subsidiary-paths-innovation-to-merge-with-universal-sequencing-technology-shares-up-83","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2332672800","content_text":"Aptorum Group (NASDAQ:APM) is up 8.3% after announcing a non-binding Letter of Intent to merge its subsidiary Paths Innovation Limited with Universal Sequencing Technology. Paths Innovation Limited, which is majority-owned by Aptorum, holds the PathsDx technology through its subsidiary Paths Diagnostics. This liquid biopsy Next-Generation Sequencing (NGS) technology is used for diagnosing infectious diseases. As part of the transaction, upon closing, Aptorum's subsidiary Aptorum Therapeutics will become a shareholder in the combined company. Press Release","news_type":1},"isVote":1,"tweetType":1,"viewCount":847,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":11,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}